SAB Biotherapeutics (SABS) Non-Current Assets (2020 - 2026)

SAB Biotherapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $135.7 million for Q1 2026.

• Quarterly Non-Current Assets rose 521.76% year-over-year to $135.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $298.4 million (up 247.84% YoY) and the FY2025 annual result came in at $71.8 million, up 251.7% from the prior year.
• Non-Current Assets was $135.7 million for Q1 2026 at SAB Biotherapeutics, up from $71.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $135.7 million in Q1 2026 and bottomed at $20.4 million in Q4 2024.
• A 5-year average of $37.3 million and a median of $26.4 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 73.89% — and 2026, when it jumped 521.76%.
• SAB Biotherapeutics' Non-Current Assets stood at $28.8 million in 2022, then dropped by 13.1% to $25.0 million in 2023, then slipped by 18.5% to $20.4 million in 2024, then surged by 251.7% to $71.8 million in 2025, then surged by 89.09% to $135.7 million in 2026.
• Business Quant data shows SABS's Non-Current Assets at $135.7 million in Q1 2026, $71.8 million in Q4 2025, and $70.2 million in Q3 2025.